NEWS
PROALT attended at BIO 2017 International Convention in San Diego (USA)
22nd, June 2017 PROALT was present at BIO 2017 International Convention in San Diego CA (USA) from 19 to 22 June. The company exhibited all its business activities in a booth located within the Spanish pavilion, where several contacts with companies' representatives were celebrated, and also participated in the partnering area (business forum) to have [...]
PROALT exhibits and presented at the investment forum in BIOSPAIN 2016
3rd, October 2016 PROALT has attended BIOSPAIN 2016. This year's event has been held from 28th to 31st September 2016 in Bilbao (Spain). PROALT participated with a booth at the exhibition area of BioSpain. PROALT also met other attendees during the business partnering and presented its business project at the Investment Forum. [...]
PROALT attended the BIO 2016 International Convention in San Francisco
10th, June 2016 PROALT has participated in BIO International Convention 2016. The event has been held in San Francisco (United States) from 6 to 9 June 2016 . The Spanish Pavillion was organized by ICEX (Spain Trade and Investment) and The Spanish Trade Commission in Chicago, and brought together other 52 companies and Spanish biotech [...]
Presentation of ColoDetect project in the European Commission booth at BIO 2016
10th, June 2016 PROALT has been selected by Enterprise Europe Network (EEN) as a successfully funded company and invited to present its ColoDetect project in the European Commission's booth #5977 at BIO International Convention trade fair. The event, hold in San Francisco (United States), took place on Wednesday 8 June 2016. PROALT presented the key [...]
PROALT has launched ColoDetect website to disseminate project results
1st, April 2016 ColoDetect project announces the launch of its website. ColoDetect is a project funded by the European Union through the H2020 SME Instrument Phase 2 and developed by Protein Alternatives (PROALT). The project started in October 2015 and will run for three years. Its objective is the development and commercialization of a blood-based [...]
